HERZUMA is a prescription medicine used in adults for the treatment of early-stage breast cancer that is H uman E pidermal growth factor R eceptor 2 -positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes.

OGIVRI is a prescription medicine used for the treatment of adjuvant breast cancer. OGIVRI is used for the treatment of early-stage breast cancer that is H uman E pidermal growth factor R eceptor 2 -positive (HER2+) and has spread into the lymph nodes or is HER2-positive and has not spread into the lymph nodes.

Herceptin was the first HER2-targeted therapy for breast cancer. It is a monoclonal antibody that binds to HER2 receptors present on the surface of HER2-positive tumour cells, blocking them from receiving growth signals and flagging them for destruction by the immune system.

Trastuzumab is a monoclonal antibody targeting HER2, inducing an immune-mediated response that causes internalization and recycling of HER2. It may also upregulate cell cycle inhibitors such as p21 Waf1 and p27 Kip1.

See risks & benefits. Learn about TRAZIMERA™ (trastuzumab-qyyp), an FDA-approved biosimilar of HERCEPTIN® (trastuzumab), on the official patient website.

ONTRUZANT is a prescription medicine approved for the treatment of HER2+ breast cancer. It can be used in combination with certain chemotherapy drugs or alone after treatment with …

曲妥珠單抗 （通用名， 國際非專利藥品名稱： Trastuzumab，商品名： 赫賽汀 （中國大陸及港澳）、 賀癌平 （台灣），羅氏Roche藥廠生產）是一種作用於 人類表皮生長因子受體II 的 單株抗體，主要用於治療某些HER-2陽性乳癌。

Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). [11][12] It is licensed for the treatment of breast cancer or gastric or gastroesophageal ...

This activity outlines trastuzumab's various indications and off-label uses, including its combination with anthracycline or taxane-based chemotherapy for breast cancer, as monotherapy or in combination with paclitaxel for metastatic breast cancer, and in combination with cisplatin-based chemotherapy for gastric cancer.

HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) is approved for the treatment of adults with early-stage breast cancer that is H uman E pidermal growth factor R eceptor 2 …